AlphaMaven AlphaMaven
Private Equity

Avista taps Tom Orr as strategic executive

Reported by Pehub
Aug 24, 2026· 1 min read
Save Post LinkedIn Email
Key Takeaways
  • • Avista appoints Tom Orr as strategic executive, elevating his role from chairman of Bentec Medical, a portfolio company within the Avista organization.
  • • Orr's appointment reflects Avista's focus on leveraging experienced leadership across its portfolio of companies to drive strategic initiatives.
  • • The move indicates potential expansion or repositioning efforts within Avista's healthcare or medical device investment strategy, given Bentec Medical's sector focus.
Summary
Avista has named Tom Orr to a strategic executive position, marking a promotion for the experienced healthcare executive. Orr previously served as chairman of the board of Bentec Medical, which operates as a portfolio company within Avista's investment holdings.

The appointment signals Avista's commitment to deploying senior talent across its platform companies to accelerate growth and operational improvements. By elevating Orr to a broader strategic role, Avista appears to be positioning him to apply his healthcare and medical device expertise across multiple investments or to lead enterprise-wide initiatives.

Details regarding Orr's specific responsibilities, reporting structure, and scope of authority in this new strategic executive position were not disclosed in available sources. The timing and scope of this executive transition will likely inform investor expectations regarding Avista's portfolio company performance and strategic direction going forward.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Pehub Avista taps Tom Orr as strategic executive

Not a member yet?

Why AlphaMaven

The Alternative Investment
Intelligence Platform

Access nearly 1 million industry profiles in alternative investments — firms, funds, decision-makers and regulatory filings.

Start a free 7-day trial — card required, cancel anytime
Data · Intelligence · ROI
Company, fund & contact directory
Screener with filters & saved searches
Regulatory data — SEC, NFA, GLEIF, Form D
Manager-reported fund performance
11K+ members contributing data
Daily news with AI executive summaries
Data exports from your tracked list
Research guides, leaderboards & glossary
211,600+
Firms
627,900+
Decision-Makers
70,000+
Data Sources
Start your free 7-day trial

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.